6533b7d5fe1ef96bd12652b3
RESEARCH PRODUCT
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis
D GinardI Marin-jimenezM Barreiro-de AcostaE RicartE DomenechJp GisbertM EsteveM MinguezRepresentacion Geteccusubject
glucocorticoidesmedicine.medical_specialtycolitisAdministration TopicalhumanosAnti-Inflammatory AgentsTopical treatmentmesalamina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMesalazineTopical treatmentmedicineMesalazinaHumansCorticosteroidsMesalamineGlucocorticoidsCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseantiinflamatoriosUlcerative colitisDermatologyClinical PracticechemistryUlcerative colitis030220 oncology & carcinogenesisDisease remission030211 gastroenterology & hepatologyColitis UlcerativeMesalazinebusinessdescription
Although most patients with ulcerative colitis should be given topical treatment, different studies have shown that they are underused in clinical practice. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission are evaluated. Finally, a series of recommendations addressed to patients are given on the correct application of topical treatment. (C) 2019 The Authors. Published by Elsevier Espana, S.L.U.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-02-01 |